title: [Combined application of non-specific activated immunocytes and cisplatin to treat hemangioendothelioma EOMA xenografts].
abstract: OBJECTIVE
  To investigate the possibility of combined non-specific activated splenocytes (aSplenocytes) and cisplatin in treating murine hemangioendothelioma EOMA cell line.
  
  
  METHODS
  The effects of cisplatin, aSplenocytes or both on EOMA cells were measured by MTT assay and trypan blue exclusive method, respectively. EOMA-bearing mice were established by subcutaneous inoculation of 1.5x10(6) EOMA cells in 6-week old male BALB/c nu/nu mice, divided into untreated control, cisplatin group, aSplenocytes group, and combination group, 5 mice per group. Tumor was treated with 1.5x10(6) aSplenocytes per 100 microL via intratumoral injection, and 24 hours later, followed by cisplatin treatment via intraperitoneal injection. Cisplatin treatment was repeated once a week at the dose of 8 mg/kg of body weight. Tumor volume was measured at indicated time.
  
  
  RESULTS
  Both cisplatin and aSplenocytes had inhibitory effects on EOMA cells. 47.7%+/-5.9% EOMA cells were found in 100 micromol/L cisplatin-treated EOMA cells for 24 hours. 42.8%+/-2.6% and 45.3%+/-2.2% EOMA cells were in survival in 1x10(5) /mL aSplenocytes-treated EOMA cells in cell-cell direct contact co-culture system and in transwell system for 48 hours, respectively. When EOMA cells were sensitized with 1x10(5) aSplenocytes in cell-cell direct contact system or in transwell system for 24 hours, followed with 100 micromol/L cisplatin for additional 24 hours, only 25.0%+/-2.7% and 27.5%+/-3.8% EOMA cells were in survival. Compared with single-agent alone treatments, aSplenocytes plus cisplatin significantly inhibited the growth of EOMA cells (P<0.05). There was no significant difference in EOMA cell survival between the two co-culture systems (P>0.05). In vivo assay showed the tumor volume was (680.3+/-68.0) mm3, (825.2+/-71.8) mm3, (535.3+/-74.5) mm3 and (351.5+/-79.5) mm3 in the control, aSplenocytes, cisplatin and aSplenocytes plus cisplatin group, respectively, on the 18 th day after treatment. aSplenocytes plus cisplatin markedly delayed EOMA tumor growth (P<0.05).
  
  
  CONCLUSIONS
  aSplenocytes could enhance the cytotoxicity of cisplatin in EOMA cells in vitro and in vivo.
authors.affiliation: Research Laboratory of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing 100081, China.
authors.forename: Yi-xiang
authors.initials: YX
authors.lastname: Wang
authors.forename: Zhen-qi
authors.initials: ZQ
authors.lastname: Xu
authors.forename: Yu
authors.initials: Y
authors.lastname: Liu
authors.forename: Sheng-lin
authors.initials: SL
authors.lastname: Li
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology* / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006390:Hemangioendothelioma / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D013154:Spleen / Q000166:cytology / Q000276:immunology*
chemical_list: D002945:Cisplatin